title: Osteogenesis mechanism of chitosan-coated calcium sulfate pellets on the restoration of segmental bone defects.
abstract: A radial segmental defect model of a rabbit was used to study the restoration effect on defects treated with chitosan-coated pressed calcium sulfate pellets combined with recombinant human bone morphogenetic protein-2 (rhBMP-2), coated pressed calcium sulfate pellets, and uncoated pressed calcium sulfate pellets. Nothing was implanted in the control group. After 4, 8, and 12 weeks, the results indicated that coated pressed calcium sulfate pellets combined with rhBMP-2 and coated pressed calcium sulfate pellets facilitated new bone formation on defected bones and that, particularly, the coated pressed calcium sulfate pellets combined with rhBMP-2 was more effective than the coated pressed calcium sulfate pellet. Histologic and tetracycline fluorimetric findings showed that the osteogenesis mechanism of chitosan-coated pressed calcium sulfate pellets is membrane bone formation, and the pellets showed slightly slower resorption that closely coincides with the growth rate of new bone.
authors.affiliation: Department of Orthopaedics, Dalian University Affiliated Zhongshan Hospital, Dalian, China. cuixuprossor@163.com
authors.forename: Xu
authors.initials: X
authors.lastname: Cui
authors.forename: Dewei
authors.initials: D
authors.lastname: Zhao
authors.forename: Boxun
authors.initials: B
authors.lastname: Zhang
authors.forename: Yongliang
authors.initials: Y
authors.lastname: Gao
mesh_terms: D020341:Absorbable Implants; D000818:Animals; D015519:Bone Density / Q000187:drug effects; D001847:Bone Diseases / Q000473:pathology / Q000601:surgery*; D001853:Bone Marrow / Q000473:pathology; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D018786:Bone Substitutes / Q000627:therapeutic use*; D002113:Calcification, Physiologic / Q000187:drug effects; D002133:Calcium Sulfate / Q000627:therapeutic use*; D048271:Chitosan / Q000627:therapeutic use*; D020099:Coated Materials, Biocompatible / Q000627:therapeutic use*; D003238:Connective Tissue / Q000473:pathology; D018483:Diaphyses / Q000473:pathology / Q000601:surgery; D004195:Disease Models, Animal; D005456:Fluorescent Dyes; D005470:Fluorometry; D006801:Humans; D010012:Osteogenesis / Q000187:drug effects*; D011817:Rabbits; D011884:Radius / Q000473:pathology / Q000601:surgery; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D013314:Stress, Mechanical; D013752:Tetracycline; D013997:Time Factors; D016212:Transforming Growth Factor beta / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D018786:Bone Substitutes; D020099:Coated Materials, Biocompatible; D005456:Fluorescent Dyes; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2; D048271:Chitosan; D013752:Tetracycline; D002133:Calcium Sulfate